Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Progressive multifocal leukoencephalopathy (PML) remains a rare but serious demyelinating disease affecting immunocompromised individuals. According to Saimounika Adapa et al., approximately 4,000 PML diagnoses are reported annually across the United States and European Union, while JC polyomavirus seroprevalence is estimated at 40-60% of the global population. According to the Progressive Multifocal Leukoencephalopathy (PML) Epidemiology Forecast by Expert Market Research, the disease continues to represent a significant clinical burden due to its high mortality risk, association with severe immunosuppression, and increasing occurrence among patients receiving immunomodulatory therapies.
2025
Base Year
2019-2025
Historical Period
2026-2035
Forecast Period
Read more about this report - Request a Free Sample
Progressive Multifocal Leukoencephalopathy (PML) Epidemiology Forecast Report Coverage
Expert Market Research's “Progressive Multifocal Leukoencephalopathy (PML) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of progressive multifocal leukoencephalopathy (PML). It projects the future incidence and prevalence rates of Progressive Multifocal Leukoencephalopathy (PML) cases across various populations. The study covers age, gender, and type as major determinants of the progressive multifocal leukoencephalopathy (PML) population. The report highlights patterns in the prevalence of progressive multifocal leukoencephalopathy (PML) over time and projects future trends based on multiple variables.
The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of progressive multifocal leukoencephalopathy (PML) in the 8 major markets.
Regions Covered
- United States
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Progressive Multifocal Leukoencephalopathy (PML) Understanding: Disease Overview
Progressive multifocal leukoencephalopathy (PML) is a rare and potentially fatal disorder of the central nervous system caused by reactivation of the John Cunningham (JC) polyomavirus in immunocompromised individuals. PML is characterized by multifocal demyelination resulting from lytic infection of oligodendrocytes and, in many cases, atypical astrocytes. The disease commonly occurs in patients with acquired immunodeficiency syndrome (AIDS), hematological malignancies, organ transplantation, or immunosuppressive therapies. As per published studies, the condition manifests through multifocal neurological deficits and represents a severe neurological disorder associated with immune dysfunction.
Key Report Insights
|
Parameter |
Insight |
|
Largest Patient Pool |
United States |
|
Fastest Growing Region |
Japan |
|
High-Risk Population |
Immunocompromised patients |
|
Key Diagnostic Method |
Clinical assessment |
|
Major Risk Factor |
Severe cellular immunodeficiency |
|
Major gap in the market |
Limited disease-specific therapies |
Progressive Multifocal Leukoencephalopathy (PML) Epidemiology Perspective
The progressive multifocal leukoencephalopathy (PML) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the progressive multifocal leukoencephalopathy (PML) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for progressive multifocal leukoencephalopathy (PML) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.
|
Epidemiology Segment |
Key Insights |
|
Diagnosed Prevalent Cases of the Disease |
According to Saimounika Adapa et al., approximately 4,000 diagnoses of Progressive Multifocal Leukoencephalopathy are reported annually across the combined United States and European Union, highlighting the persistent burden among immunocompromised populations. |
|
Gender-Specific Cases of the Disease |
According to Hiromichi Otaka et al., males represented 62.8% of reported PML cases in Japan, indicating a higher documented disease burden among men within the evaluated patient population. |
|
Age-Specific Cases of the Disease |
Published findings by Hiromichi Otaka et al., the median age of hospitalized patients with PML in Japan was 62 years, suggesting a greater disease burden among older adults and aging immunocompromised populations. |
|
Ethnicity-Wise Cases of the Disease |
Available epidemiological evidence indicates that disease occurrence is primarily associated with immune status and underlying medical conditions rather than ethnicity, with reported cases observed across diverse global populations. |
|
Mortality and Survival Analysis of the Disease |
According to Marie-Ghislaine de Goër de Herve et al., one-year mortality in France was 38.2%. As per Alexandre Chevalier et al., one-year survival reached 62% among patients receiving polyomavirus-specific T-cell therapy. |
Type-Specific Disease Burden and Epidemiology Analysis
|
Disease Type |
Prevalence |
|
HIV/AIDS-Associated PML |
According to published studies, HIV/AIDS-associated PML represents a major disease subtype and has historically accounted for a significant proportion of cases due to profound immune suppression associated with advanced HIV infection. |
|
Drug-Induced / Iatrogenic PML |
As per reported findings, drug-induced PML is a prominent subtype associated with immunomodulatory and immunosuppressive therapies, with increasing clinical importance owing to the growing use of biologic and targeted treatments. |
|
Malignancy-Associated PML |
According to available evidence, malignancy-associated PML constitutes a substantial share of the disease burden, particularly among patients with hematological cancers and those undergoing intensive immunosuppressive treatment. |
|
Others |
Other forms of PML include autoimmune-associated PML, inflammatory PML, PML-related immune reconstitution inflammatory syndrome (PML-IRIS), JC virus granule cell neuronopathy, and JC virus encephalopathy, which collectively represent a smaller but clinically important segment of cases. |
Read more about this report - Request a Free Sample
Country-wise Progressive Multifocal Leukoencephalopathy (PML) Epidemiology
The progressive multifocal leukoencephalopathy (PML) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.
|
Country |
Key Insights |
|
United States |
According to Marie-Ghislaine de Goër de Herve et al., the overall incidence of PML was estimated at 0.5 per 100,000 person-years, representing one of the highest reported incidence rates among evaluated countries. |
|
Germany |
As per the epidemiological evidence from European studies, PML remains a rare disease primarily affecting immuno-compromised populations, with disease burden linked to underlying immune dysfunction. |
|
France |
Marie-Ghislaine de Goër de Herve et al., estimated that the overall incidence was around 0.11 per 100,000 person-years, while one-year mortality reached 38.2%. |
|
Italy |
As per reported European epidemiological findings, PML remains an uncommon but severe neurological complication among patients with significant immunosuppression. |
|
Spain |
According to available European epidemiological evidence, disease occurrence is predominantly associated with AIDS, hematological malignancies, transplantation, and immunomodulatory therapies. |
|
United Kingdom |
As per published epidemiological literature, PML continues to represent a rare opportunistic infection concentrated among high-risk immunocompromised patient populations. |
|
Japan |
According to Marie-Ghislaine de Goër de Herve et al., incidence was estimated at 0.029 per 100,000 person-years. Hiromichi Otaka et al. identified 610 diagnosed cases, with admissions showing an increasing trend over time. |
|
India |
According to available published evidence, PML remains a rare opportunistic neurological disease primarily associated with severe immunosuppression and underlying immune-compromising conditions. |
Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape
According to published studies, significant gaps remain in the epidemiological characterization and early diagnosis of progressive multifocal leukoencephalopathy, particularly across several regional markets. As per reported findings, disease surveillance remains limited despite increasing use of immunosuppressive therapies and immunomodulatory agents. Emerging opportunities include expanded monitoring of high-risk populations, improved diagnostic pathways, and broader adoption of immune-based therapeutic approaches. The growing research into polyomavirus-specific T-cell therapies and biomarkers associated with survival outcomes may support more effective disease management and improve long-term patient outcomes across major healthcare markets.
Progressive Multifocal Leukoencephalopathy (PML): Treatment Overview
The management of progressive multifocal leukoencephalopathy (PML) primarily focuses on restoring immune function and controlling the underlying immunosuppressive condition. The treatment strategies include reduction of immunosuppressive therapies when feasible and supportive neurological care. As per Alexandre Chevalier et al., polyomavirus-specific T-cell therapy has emerged as a promising therapeutic approach, with one-year survival reaching 62% among evaluated patients. Published findings also indicate that lower cerebrospinal fluid JC polyomavirus DNA levels are associated with improved outcomes. Ongoing research continues to explore innovative immune reconstitution strategies for disease management.
Key Questions Answered
- What is the current and projected burden of progressive multifocal leukoencephalopathy (PML) across the 8 major markets?
- Which countries across the 8 major markets account for the highest progressive multifocal leukoencephalopathy (PML) patient populations and fastest growth rates?
- What is the diagnosed versus undiagnosed patient population of progressive multifocal leukoencephalopathy (PML) across key countries in the 8 major markets?
- Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of progressive multifocal leukoencephalopathy (PML) across the 8 major markets?
- What are the major drivers contributing to the increasing burden of progressive multifocal leukoencephalopathy (PML) across the 8 major markets?
- How do major comorbidities and risk factors influence progressive multifocal leukoencephalopathy (PML) epidemiology trends across the 8 major markets?
- What are the regional trends in advanced disease progression, treatment uptake, and patient management of progressive multifocal leukoencephalopathy (PML) across the 8 major markets?
- Which patient segments represent the highest unmet clinical need in the progressive multifocal leukoencephalopathy (PML) landscape across the 8 major markets?
- Which therapeutic areas linked to progressive multifocal leukoencephalopathy (PML) are expected to witness the strongest growth opportunities across the 8 major markets?
- How is the progressive multifocal leukoencephalopathy (PML) epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
- Which countries across the 8 major markets offer the most attractive market opportunities based on progressive multifocal leukoencephalopathy epidemiology and healthcare infrastructure?
- Which epidemiological trends are expected to influence future drug development and market access strategies for progressive multifocal leukoencephalopathy (PML) across the 8 major markets?
Scope of the Progressive Multifocal Leukoencephalopathy (PML) Epidemiology Report
- The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of progressive multifocal leukoencephalopathy (PML) based on several factors.
- Progressive Multifocal Leukoencephalopathy (PML) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
- The progressive multifocal leukoencephalopathy (PML) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$2999 $2699
-
$4399 $3739
-
$5799 $4929
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Report Features |
Details |
|
Base Year |
2025 |
|
Historical Period |
2019-2025 |
|
Forecast Period |
2026-2035 |
|
Epidemiology Statistics Provided |
|
|
Segmentation Provided |
|
|
Geographies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 2,999
USD 2,699
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,399
USD 3,739
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,799
USD 4,929
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
